CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 811,773	$ 535,203
Marketable securities	495,311	503,481
Accounts receivable - trade, net	1,339,794	1,343,368
Accounts Receivable from Sanofi	214,269	92,989
Accounts receivable from Bayer	195,485	175,263
Inventories	466,576	399,356
Prepaid expenses and other current assets	146,055	130,528
Total current assets	3,669,263	3,180,188
Marketable securities	967,695	864,260
Property, plant, and equipment, net	2,277,029	2,083,421
Deferred tax assets	866,291	825,303
Other assets	37,087	20,294
Total assets	7,817,365	6,973,466
Current liabilities:
Accounts payable and accrued expenses	1,061,777	879,096
Capital and facility lease obligations, current	7,200	129,557
Deferred revenue from Sanofi, current portion	112,161	115,267
Deferred Revenue, Current	126,257	116,397
Other current liabilities	876	1,178
Total current liabilities	1,308,271	1,241,495
Deferred revenue from Sanofi	520,191	503,474
Deferred Revenue, Noncurrent	316,227	327,298
Capital and facility lease obligations	700,407	351,569
Other long-term liabilities	106,248	100,385
Total liabilities	2,951,344	2,524,221
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	3,190,882	3,029,993
Retained earnings	1,997,153	1,748,222
Accumulated other comprehensive income	(5,884)	(12,840)
Treasury stock	(316,240)	(316,240)
Total stockholders' equity	4,866,021	4,449,245
Total liabilities and stockholders' equity	7,817,365	6,973,466
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 108	$ 108